InnoStars Talks with Maurizio Ferrari, Chief Medical Officer at SYNLAB Italy

In the latest episode of InnoStars Talks, we dive deep into the cutting-edge world of healthcare innovation with Maurizio Ferrari, Chief Medical Officer at SYNLAB Italy. As a global leader in diagnostics, SYNLAB operates in 33 countries, employing over 27,000 people and performing more than 600 million tests annually. Their unwavering commitment to innovation and actionable diagnostics is transforming the global healthcare landscape.

“Innovation in this century is mandatory for any type of activity. If you aren’t able to innovate, you lose something. Losing means a loss for the patient,” Ferrari passionately explains. This sentiment underscores SYNLAB’s relentless pursuit of advancements that ensure better patient outcomes.
The episode also delves into the transformative power of technological innovation, artificial intelligence (AI), and sustainability. Ferrari emphasizes the critical role of AI in healthcare, advocating for its proper use to extract meaningful information and deliver clear, actionable insights to patients. He also highlights the dual benefits of sustainability, which enhances business operations while improving patient care.
A notable highlight is SYNLAB’s partnership with EIT Health. This collaboration has led to the development of the world’s first blood-based test for differentiating between bipolar disorder and unipolar depression—EDIT-B. This revolutionary diagnostic tool exemplifies the profound impact of innovative partnerships in healthcare.
Don’t miss this insightful episode of InnoStars Talks to discover more about SYNLAB’s pioneering journey and learn how start-ups can harness similar opportunities for growth and success. Tune in and get inspired by the future of healthcare innovation.

Interested in getting updates on new episodes of InnoStars Talks? Subscribe to our newsletter!